These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22565535)

  • 1. Emerging therapies for residual risk.
    Mehra S; Movahed H; Movahed A
    Rev Cardiovasc Med; 2012; 13(1):e24-31. PubMed ID: 22565535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.
    Xian Y; Navar AM; Li S; Li Z; Robinson J; Virani SS; Louie MJ; Koren A; Goldberg A; Roger VL; Wilson PWF; Peterson ED; Wang TY
    J Am Heart Assoc; 2019 Oct; 8(19):e013229. PubMed ID: 31554462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.
    Munkhaugen J; Sverre E; Otterstad JE; Peersen K; Gjertsen E; Perk J; Gullestad L; Moum T; Dammen T; Husebye E
    Eur J Prev Cardiol; 2017 Jun; 24(9):981-989. PubMed ID: 28196429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
    Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
    Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
    Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease.
    Genest J
    Can J Cardiol; 2006 Aug; 22(10):863-8. PubMed ID: 16957804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins do not decrease small, dense low-density lipoprotein.
    Choi CU; Seo HS; Lee EM; Shin SY; Choi UJ; Na JO; Lim HE; Kim JW; Kim EJ; Rha SW; Park CG; Oh DJ
    Tex Heart Inst J; 2010; 37(4):421-8. PubMed ID: 20844614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to Overcome Residual Risk During Statins Era.
    Cho KI; Yu J; Hayashi T; Han SH; Koh KK
    Circ J; 2019 Sep; 83(10):1973-1979. PubMed ID: 31391351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies.
    Gragnano F; Calabrò P
    Atherosclerosis; 2018 Feb; 269():219-228. PubMed ID: 29407597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.